C-MYC and BCL2 Translocation Frequency in Diffuse Large B-Cell Lymphomas: A Study Of 97 Patients

dc.contributor.authorAkkaya, Bahar
dc.contributor.authorSalim, Ozan
dc.contributor.authorAkkaya, Hampar
dc.contributor.authorOzcan, Mualla
dc.contributor.authorYucel, Orhan Kemal
dc.contributor.authorErdem, Ramazan
dc.contributor.authorIltar, Utku
dc.contributor.authorUndar, Levent
dc.contributor.orcIDhttps://orcid.org/0000-0002-7070-6901en_US
dc.contributor.pubmedID26960633en_US
dc.contributor.researcherIDABG-2028-2020en_US
dc.date.accessioned2023-07-31T10:50:37Z
dc.date.available2023-07-31T10:50:37Z
dc.date.issued2016
dc.description.abstractPurpose: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with marked biologic heterogeneity. MYC and BCL2 rearrangements have been reported in a proportion of DLBCLs, where they may be associated with an adverse clinical outcome. The aim of this study was to determine the frequency of MYC and BCL2 translocations in DLBCL and assess the prognostic impact in DLBCL patients. Materials and Methods: HAIR SPACE In the present study, we evaluated the expression patterns of CD 10, BCL6, and MUM 1 by immunohistochemistry in 121 cases with DLBCL in tissue microarray (TMA): 62 cases in germinal center B-cells (GCBs); and 59 cases in activated B-cells (ABCs) of which 60 were females and 61 were males. MYC and BCL2 rearrangements were investigated by interphase fluorescence in situ hybridization on TMAs in 97 DLBCLs. Result: MYC rearrangements were observed in 11 of 97 cases. There was no association with other clinical features, including age, sex, and nodal/extranodal disease. MYC rearrangement was associated with significantly worse overall survival (P < 0.01). BCL2 rearrangements were observed in 14 of 97 cases. There was no association with other clinical features including age and sex. BCL2 rearrangement had a worse outcome (P < 0.01). MYC and BCL2 rearrangements were observed in 3 of 97 cases with the age ofHAIR SPACE 53 (female), 53, 63 years old, respectively, died in 24, 18, and 35 months after the diagnosis. Two cases had primary nodal and one case primary extranodal presentations. All these patients had stage IV disease. Conclusion: We concluded that C-MYC and BCL2 may contribute to aggressive transformation, and more mechanism-based therapy should be explored. Targeted therapies involving these rearrangements and its associated pathways may change the fate of DLBCLs. Analysis of MYC gene rearrangement along with BCL2 is critical in the identification of high-risk patients with poor prognosis.en_US
dc.identifier.endpage46en_US
dc.identifier.issn0377-4929en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84961843592en_US
dc.identifier.startpage41en_US
dc.identifier.urihttp://hdl.handle.net/11727/10098
dc.identifier.volume59en_US
dc.identifier.wos000372966600009en_US
dc.language.isoengen_US
dc.relation.isversionof10.4103/0377-4929.178220en_US
dc.relation.journalINDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBCL2en_US
dc.subjectdiffuse large B-cell lymphomaen_US
dc.subjectdouble-hit lymphomaen_US
dc.subjectFISHen_US
dc.subjectMYCen_US
dc.titleC-MYC and BCL2 Translocation Frequency in Diffuse Large B-Cell Lymphomas: A Study Of 97 Patientsen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: